Additional file 1

Combination effects of amino acid transporter LAT1 inhibitor nanvuranlat and cytotoxic anticancer drug gemcitabine on pancreatic and biliary tract cancer cells

Kou Nishikubo¹, Ryuichi Ohgaki^{1, 2}, Xingming Liu¹, Hiroki Okanishi¹, Minhui Xu¹, Hitoshi Endou³ and Yoshikatsu Kanai^{1,2}

¹Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan ²Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan ³J-Pharma Co., Ltd., Yokohama, Japan

Correspondence

Yoshikatsu Kanai and Ryuichi Ohgaki, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Email: <u>ykanai@pharma1.med.osaka-u.ac.jp</u>, <u>ohgaki@pharma1.med.osaka-u.ac.jp</u> TEL: 06-6879-3521 FAX: 06-6879-3529

Additional file 1




Figure S1

Combination effects of gemcitabine and nanvuranlat on cell growth by sequential treatments. A The treatment schedule of single or simultaneous treatments with gemcitabine (GEM) and nanvuranlat (NANV). According to the schedule, MIA PaCa-2 and KKU-055 cells were treated with GEM or NANV, or both. After 36 h of the first treatment, the medium was removed, washed once with 100 µL of the medium, and replaced with fresh medium containing drugs for a further 36 h of treatment (72 h in total). B Cell growth inhibition was analyzed by Cell Counting Kit-8 after 72 h of the treatments. Cells were treated with drugs at the following concentrations: MIA PaCa-2 (GEM; 13 nmol/L, NANV; 3 µmol/L), KKU-055 (GEM; 10 nmol/L, NANV; 0.9 µmol/L). Data were normalized for non-treated controls and shown as mean \pm SEM (n = 8). Statistical significance was evaluated by one-way ANOVA followed by Tukey's post-test.